Description: Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.
Home Page: www.bauschhealth.com
BHC Technical Analysis
2150 St. ElzEar Boulevard West
Laval,
QC
H7L 4A8
Canada
Phone:
514-744-6792
Officers
Name | Title |
---|---|
Mr. Thomas J. Appio | CEO & Director |
Mr. Thomas G. Vadaketh | Exec. VP & CFO |
Mr. Mirza Dautbegovic | Sr. VP & COO |
Mr. John S. Barresi | Sr. VP, Controller & Chief Accounting Officer |
Dr. Robert F. Butz | VP of Medical & Scientific Affairs |
Mr. Arthur J. Shannon | Sr. VP and Head of Investor Relations & Global Communications |
Ms. Seana Carson | Exec. VP & Gen. Counsel |
Ms. Kathleen Fitzpatrick | Sr. VP & Chief HR Officer |
Dr. Tage Ramakrishna M.D. | Chief Medical Officer and Pres of R&D |
Mr. Jeff Hartness | Sr. VP of Market Access, Commercial Operations & Gov. Affairs |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
Forward PE: | 2.0597 |
---|---|
Trailing PE: | 10.3608 |
Price-to-Book MRQ: | 18.7424 |
Price-to-Sales TTM: | 0.4693 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 19600 |